ENDOMETRIAL CARCINOMA-ASSOCIATED WITH ADJUVANT TAMOXIFEN THERAPY FOR BREAST-CANCER - A FRENCH MULTICENTER ANALYSIS OF 89 CASES

Tamoxifen has been used for two decades as adjuvant therapy for breast cancer. It is also now being used to try and prevent this disease in women at high risk. A series of 89 patients who developed endometrial cancer on adjuvant has been identified from nine French cancer institu tes. Although there was a high frequency of superficial, generally cel l-differentiated forms, some patients did have aggressive disease with a relatively poor outcome and there were 10 deaths from endometrial c arcinoma, These data support gynaecological surveillance of women rece iving tamoxifen therapy.